Related coverage linked through entity extraction aliases.
Aug 09, 2026
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Jul 29, 2026
Colorectal Cancer Alliance tackles rising young-onset cases with Never Too Young Taskforce and Project Cure CRC; LEAD FROM BEHIND wins Webby Award. Screening changes make 20M more eligible.
Jul 31, 2026
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Aug 02, 2026
A study finds that FABP2 suppresses colon cancer liver metastasis by increasing ferroptosis sensitivity via β-catenin/GPX4 pathway regulation. Low FABP2 expression correlates with poor survival in advanced colon cancer.
Aug 01, 2026
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
Jun 02, 2026
Rural cancer death rates are highest while big-city rates are lowest, a study of 28 million deaths found. However, separate research shows rural lung and colon cancer patients treated locally had similar outcomes to those at urban centers.
Apr 24, 2026
A study in stage 3 dMMR colon cancer found that atezolizumab plus chemotherapy after surgery cut recurrence and death risk by 50%. The trial enrolled 712 patients and the regimen is now included in treatment guidelines.
Apr 21, 2026
Karmanos and the Detroit Public Library have opened registration for the 2026 Community Conversations on Cancer series. Three sessions will address colon cancer, implicit bias in care, and multiple myeloma.
Apr 21, 2026
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
Apr 07, 2026
A novel therapeutic vaccine using structural nanomedicine principles has shown promising results against HPV-driven cancers in preclinical models. The spherical nucleic acid vaccine design significantly slowed tumor growth and extended survival by generating potent T-cell responses. Unlike preventive HPV vaccines, this approach is designed to treat established cancers caused by the virus.
Mar 19, 2026
Research into Lynch syndrome is advancing cancer prevention through aspirin therapy, vaccine trials, and a major North American study examining why some patients develop cancer while others remain protected.
Mar 19, 2026
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
Mar 05, 2026
A nationwide survey reveals 50% of Americans don't know colorectal cancer can be screened at home, as the disease becomes the leading cause of cancer death in adults under 50. Current guidelines recommend screening begin at age 45.
Mar 04, 2026
ImmunityBio establishes wholly owned subsidiary in Saudi Arabia to distribute Anktiva for bladder and lung cancer across MENA region, following world's first lung cancer approval in the Kingdom less than a year after May 2025 meeting.
Mar 02, 2026
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
